COMPARISON 1. ARIPIPRAZOLE vs placebo: ≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above)
Aripiprazole probably leads to higher ≥ 50% decrease in total YMRS from baseline at three weeks Young… compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Aripiprazole vs placebo ≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) · patients with an acute manic or mixed episode Aripiprazole probably leads to higher ≥ 50% decrease in total YMRS from baseline at three weeks Young… compared with placebo (moderate certainty). Aripiprazole alone or in combination for acute mania (2013) · Cochrane Headline outcomes only | RR 1.7 [1.23, 2.34] | 1230 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Aripiprazole alone or in combination for acute mania 2013 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.